Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus.

Lekakis J, Ikonomidis I, Palios J, Tsiodras S, Karatzis E, Poulakou G, Rallidis L, Antoniadou A, Panagopoulos P, Papadopoulos A, Triantafyllidi H, Giamarellou H, Kremastinos DT.

Am J Hypertens. 2009 Aug;22(8):828-34. doi: 10.1038/ajh.2009.90. Epub 2009 Jun 25.

PMID:
19556973
2.

HIV infection and antiretroviral treatment: a "two-hit" model for arterial stiffness?

Schillaci G, Pucci G, De Socio GV.

Am J Hypertens. 2009 Aug;22(8):817-8. doi: 10.1038/ajh.2009.113. No abstract available.

PMID:
19638954
3.

Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients.

van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, Hoepelman AM.

J Am Coll Cardiol. 2006 Mar 21;47(6):1117-23. Epub 2006 Feb 23.

4.

Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy.

Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-Järvinen H.

Antivir Ther. 2005;10(8):925-35.

PMID:
16430198
5.

Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Fernández Cotarelo MJ, Abellán Martínez J, Guerra Vales JM, Martínez Sánchez P, Rodrigo Gómez De La Bárcena M, Salto Fernández E.

Clin Infect Dis. 2003 Oct 1;37(7):973-7. Epub 2003 Sep 10.

PMID:
13130410
6.

HIV infection, antiretroviral therapy and cardiovascular risk.

Barbaro G.

J Cardiovasc Risk. 2002 Oct;9(5):295-300. Review.

PMID:
12394324
7.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
8.

Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.

Calza L, Manfredi R, Pocaterra D, Chiodo F.

J Infect. 2008 Jul;57(1):16-32. doi: 10.1016/j.jinf.2008.02.006. Epub 2008 Mar 21. Review.

PMID:
18358535
9.

The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico.

Ramírez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, González-Ramírez I, Ponce-de-León S.

Medicine (Baltimore). 2003 Jan;82(1):39-50.

10.

Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy.

Han SH, Chin BS, Choi HK, Shin SY, Chae YT, Baek JH, Kim CO, Choi JY, Song YG, Lee HC, Kim JM.

Tohoku J Exp Med. 2009 Oct;219(2):145-53.

12.

Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy.

Matsukura M, Chu FF, Au M, Lu H, Chen J, Rietkerk S, Barrios R, Farley JD, Montaner JS, Montessori VC, Walker DC, Côté HC.

AIDS. 2008 Jun 19;22(10):1226-9. doi: 10.1097/QAD.0b013e328303be16.

PMID:
18525271
14.

Lupus anticoagulant in human immunodeficiency virus -infected patients on highly active antiretroviral therapy.

Awodu OA, Olayemi EE, Bazuaye GN, Onunu AN.

Indian J Pathol Microbiol. 2010 Jan-Mar;53(1):47-9. doi: 10.4103/0377-4929.59182.

15.

HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.

Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, Ryan E, Yakoushina T, Khan S, Mahboob R, Naseer M, Dorfman D, Sharp V; Manhattan HIV Brain Bank.

Arch Neurol. 2004 Apr;61(4):546-51.

PMID:
15096404
16.

Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

Moodie EE, Pant Pai N, Klein MB.

PLoS One. 2009;4(2):e4517. doi: 10.1371/journal.pone.0004517. Epub 2009 Feb 18.

17.

Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.

Barbaro G.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):337-43.

PMID:
16101566
18.

Long-term use of first-line highly active antiretroviral therapy is not associated with carotid artery stiffness in human immunodeficiency virus-positive patients.

Zhu H, Yuan J, Wang Y, Gao F, Wang X, Wei C, Chen J, Fan X, Zhang M.

Braz J Infect Dis. 2014 Sep-Oct;18(5):496-500. doi: 10.1016/j.bjid.2014.02.007. Epub 2014 May 10.

19.

Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy.

Palios J, Ikonomidis I, Lekakis J, Tsiodras S, Poulakou G, Antoniadou A, Panagopoulos P, Papadopoulos A, Giamarellou H, Anastasiou-Nana M, Kremastinos D.

Microcirculation. 2010 May;17(4):303-10. doi: 10.1111/j.1549-8719.2010.00023.x.

PMID:
20536743
20.

[Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].

Neumann T, Kondratieva J, Eggebrecht H, Wieneke H, Esser S, Bartel T, Erbel R.

Herz. 2005 Sep;30(6):504-9. Review. German.

PMID:
16170681

Supplemental Content

Support Center